{
    "clinical_study": {
        "@rank": "20232", 
        "brief_summary": {
            "textblock": "RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the\n      laboratory. Antineoplastons may inhibit the growth of cancer cells.\n\n      PURPOSE: This phase II trial studies the effectiveness of antineoplaston therapy in treating\n      patients who have recurrent or refractory Waldenstrom's macroglobulinemia."
        }, 
        "brief_title": "Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia", 
        "condition": [
            "Lymphoma", 
            "Multiple Myeloma and Plasma Cell Neoplasm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Lymphoma", 
                "Waldenstrom Macroglobulinemia", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Plasmacytoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the safety and possible effectiveness of antineoplastons A10 and AS2-1 in\n           patients with recurrent or refractory Waldenstrom's macroglobulinemia.\n\n        -  Describe response, tolerance to, and side effects of this regimen in these patients.\n\n      OUTLINE: This is an open-label study.\n\n      Patients receive gradually escalating doses of antineoplastons A10 and AS2-1 by intravenous\n      injection 6 times daily until the maximum tolerated dose is reached.\n\n      Treatment continues for at least 3 months in the absence of toxicity or disease progression.\n      Patients achieving complete response (CR) continue treatment for an additional 8 months\n      after reaching CR.\n\n      Tumors are measured every 2 months the first year and every 3 months the second year.\n\n      PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed recurrent or progressive Waldenstrom's macroglobulinemia\n             that is unlikely to respond to existing therapy, including surgery, radiotherapy, and\n             chemotherapy\n\n               -  Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan\n\n               -  Must have received and failed at least one standard first-line therapy (e.g.,\n                  corticosteroid/alkylator combination)\n\n          -  Biochemical evidence of Waldenstrom's macroglobulinemia\n\n               -  Abnormal proteins in serum and urine\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  At least 2 months\n\n        Hematopoietic:\n\n          -  WBC at least 2000/mm3\n\n          -  Platelet count at least 50,000/mm3\n\n        Hepatic:\n\n          -  No hepatic insufficiency\n\n          -  Bilirubin no greater than 2.5 mg/dL\n\n          -  SGOT and SGPT no greater than 5 times upper limit of normal\n\n        Renal:\n\n          -  No renal insufficiency\n\n          -  Creatinine no greater than 2.5 mg/dL\n\n          -  No history of renal conditions that contraindicate high dosages of sodium\n\n        Cardiovascular:\n\n          -  No uncontrolled hypertension\n\n          -  No history of congestive heart failure\n\n          -  No history of other cardiovascular conditions that contraindicate high dosages of\n             sodium\n\n        Pulmonary:\n\n          -  No serious lung disease, such as chronic obstructive pulmonary disease\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception during and for 4 weeks after study\n\n          -  No active infection\n\n          -  No non-malignant systemic disease\n\n          -  Not a high medical or psychiatric risk\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 4 weeks since prior immunotherapy\n\n          -  No concurrent immunomodulating agent\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks (6 weeks since nitrosoureas) since prior chemotherapy\n\n          -  No concurrent antineoplastic agents\n\n        Endocrine therapy:\n\n          -  See Disease Characteristics\n\n          -  Concurrent corticosteroids allowed\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 8 weeks since prior radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  Recovered from prior surgery\n\n        Other:\n\n          -  No prior antineoplastons\n\n          -  Prior cytodifferentiating agents allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003512", 
            "org_study_id": "CDR0000066555", 
            "secondary_id": "BC-MW-2"
        }, 
        "intervention": [
            {
                "intervention_name": "antineoplaston A10", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "antineoplaston AS2-1", 
                "intervention_type": "Drug"
            }
        ], 
        "keyword": [
            "refractory multiple myeloma", 
            "Waldenstrom macroglobulinemia"
        ], 
        "lastchanged_date": "November 16, 2008", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/BC-MW-2"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77055-6330"
                }, 
                "name": "Burzynski Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom", 
        "overall_official": {
            "affiliation": "Burzynski Research Institute", 
            "last_name": "Stanislaw R. Burzynski, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003512"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Burzynski Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 1998", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2004"
    }, 
    "geocoordinates": {
        "Burzynski Clinic": "29.76 -95.369"
    }
}